APA (7th ed.) Citation

J, N., O, A., B, G., E, K., P, B., P, H., . . . JH, C. (2017). First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. The Journal of infectious diseases, 215(1), 95. https://doi.org/10.1093/infdis/jiw500

Chicago Style (17th ed.) Citation

J, Nyombayire, et al. "First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens." The Journal of Infectious Diseases 215, no. 1 (2017): 95. https://doi.org/10.1093/infdis/jiw500.

MLA (9th ed.) Citation

J, Nyombayire, et al. "First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens." The Journal of Infectious Diseases, vol. 215, no. 1, 2017, p. 95, https://doi.org/10.1093/infdis/jiw500.